Retatrutid: Triple Agonist In recent years, with the deepening of research into the pathogenesis of metabolic diseases, the development of multi-target agonist drugs targeting multiple hormone receptors has become a hot topic. Retatrutid is a novel triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GC) receptors.
Read More